A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal)

The sociodemographic variables will include age (in years), sex (male or female), body mass index (BMI), area of residence (rural or urban), educational level (illiterate, no studies (can only read/write), primary studies, secondary studies, or university studies), cohabitation (lives alone, lives with the family, lives alone with help from a caregiver, daily, 2-3 times/week, permanent or night-time), degree of dependence (independent, dependent grade I- requires help to perform instrumental activities of daily living (IADL) at least once a day, dependent grade II- needs help to perform IADLs 2 or 3 times a day or dependent grade III- needs help to perform IADLs several times a day),working situation (unemployed, in active employment, temporarily/permanently disabled, retired, student, other, need for financial assistance (yes/no), physical activity (high, moderate/low, inactive), smoking habit (yes/no), alcohol use (yes/no).

Clinical variables will include age (at diagnosis); MM type; international staging system (ISS) disease stage; Revised-ISS (R-ISS) disease stage; SliMCRAB signs at time of diagnosis: plasma cell bone marrow infiltration greater than or equal to (>=) 60 percent (%), serum free light chain (FLC) ratio >=100, >1 focal lesion visible on magnetic resonance imaging (MRI) with 5 millimeter (mm) or greater, increased blood calcium, renal failure, anemia, bone lesions: one or more osteolytic lesion on standard radiograph, computed tomography (CT) or Positron emission tomography-CT (PET-CT); cytogenetic abnormalities at time of diagnosis (t[4;14], t[11;14], t[14;16], t[14;20], t[6;14], trisomies, d[17p], g[1q]/ others); risk according to cytogenetic profile at diagnosis (mSMART v2 and mSMART v3); previous relapses (before the latest); stem cell transplant (yes/no); eastern cooperative oncology group (ECOG: 0-4) on diagnosis.

Clinical variables include date of latest symptomatic relapse and/or refractory episode; ISS disease stage, CRAB signs; other clinical variables (plasmacytomas: medullary or extramedullary, diffuse osteopenia, fractures, neurological symptoms, infections, lactate dehydrogenase levels, paraprotein levels, free light chain levels); concomitant diseases (diabetes, neuropathy, chronic obstructive pulmonary disease, cardiovascular disease, liver failure, psychiatric and/or neurological disorders, any other secondary disorders); cytogenetic abnormalities at diagnosis; risk according to cytogenetic profile at relapse; treatment started after latest symptomatic relapse and/or refractory episode.

Type of treatment will include therapeutic group.

Sociodemographic variables will include age (in years), sex (male or female), BMI, area of residence (rural or urban), educational level (illiterate, no studies (can only read/write), primary studies, secondary studies, or university studies), cohabitation (lives alone, lives with the family, lives alone with help from a caregiver, daily, 2-3 times/week, permanent or night-time), degree of dependence (independent, dependent grade I - requires help to perform IADL at least once a day, dependent grade II - needs help to perform IADLs 2 or 3 times a day or dependent grade III - needs help to perform IADLs several times a day), need for financial assistance (yes/no), smoking habit (yes/no), alcohol use (yes/no).

Clinical variables will include- date of latest symptomatic R/R episode; SLiMCRAB signs at latest symptomatic R/R episode: plasma cell bone marrow infiltration >=60 %, serum FLC ratio >=100, >1 focal lesion visible on MRI with 5 mm or greater, increased blood calcium, renal failure, anemia, bone lesions: one or more osteolytic lesion on standard radiograph, CT or PET-CT; other clinical variables at latest symptomatic R/R episode include- plasmacytomas (medullary/extramedullary); diffuse osteopenia; fractures; neurological symptoms (MM related); infections; lactose dehydrogenase (LDH); paraprotein levels (gram per liter [g/L]) (serum and urine) free light chain levels (g/L) (serum and urine).

New relevant variables will include factors mentioned by the participant as relevant to the disease management (example, family support, employment status); type of transportation used to receive treatment; mean cost in Euros per month with transportation to receive treatment, mean of hospital visits per month since last treatment was initiated, mean scheduled and non-scheduled participant's visits to the hospital, days of hospitalization, and specialists consulted; consultations, days of hospitalization, medical appointments and specialists consulted by type of treatment.